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Purpose: Plasminogen activator inhibitor type 1 (PAI-1) inhibits the plasminogen 
activators that convert plasminogen to plasmin. In addition to initiating fibrinolysis, 
plasmin activates tissue matrix metalloproteinases, which cause degradation of the 
extracellular matrix (ECM) in the arterial wall. Elevated levels ofPAI- 1 ultimately decrease 
plasmin formation and may lead to an accumulation of ECM and arteriosclerosis. 
Methods: PAI-1 was studied by four methods in atherosclerotic (aneurysmal nd occlusive) 
and normal (organ donor) aorta: (1) PAI-1 secretion by tissue explant supernatants, 
including time course and inhibition studies; (2) tissue PAI-1 by protein extraction; (3) 
PAI-1 mRNA was quantitated by Northern analysis using glyceraldehyde-3-phosphate 
dehydrogenase to normalize for RNA loading; and (4) in situ hybridization was used to 
localize the cells that produced PAI-1 mRNA. 
Results: Supernatant PAl- 1 levels at 48 hours were 776 _+ 352 ng/ml  in 11 atherosclerotic 
aortas and 248 + 98 ng/ml  in 8 normal aortas (p < 0.005). Tissue PAL1 levels per 100 mg 
of tissue were 99 + 58 ng in 11 atherosclerotic aortas and 38 + 20 ng in 5 normal aortas 
(p < 0.05). PAI-1 mRNA levels by Northern analysis were 0.91 + 0.49 in seven athero- 
sclerotic aortas and 0.44 + 0.27 in five normal aortas. Supernatant time-course xperi- 
ments revealed that PAI-1 increased over time. Inhibitor studies revealed that PAI-1 
decreased toapproximately one third of control values when cydoheximide oraetinomycin 
D were added to the media, indicating that active synthesis of PAI-1 had occurred. In-situ 
hybridization localized PAI-1 mRNA predominately to endothelial cells and a few 
scattered vascular smooth muscle and inflammatory cells. Subgroup analysis revealed no 
statistically significant differences between aneurysmal nd occlusive PAl- 1 levels in any of 
the experiments. 
Conclusion: PAI-1 secretion, as measured by tissue explant supernatants, and total tissue 
PAI-I in the protein extracts were significantly increased in atherosclerotic aorta. This 
elevation was also observed in the mRNA, which suggests that the increase iscontrolled at 
the level of transcription. PAId mRNA was localized to endothelial, vascular smooth 
muscle, and inflammatory cells. We conclude that elevated levels of PAI-1 exist in diseased 
aorta. These elevated levels may lead to an accumulation ofECM, thereby contributing to 
the arteriosclerosis found in aortic occlusive and aneurysmal disease. (J Vasc Surg 
1996;23:810-8.) 
Plasminogen activator inhibitor type 1 (PM-1) is 
a major inhibitor of the plasminogen activators. These 
activators, which include tissue-type plasminogen ac- 
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tivator (tPA) and uroldnase-type lasminogcn activa- 
tor (uPA), are responsible for the proteolytic leavage 
that converts the proenzyme plasminogen into the 
active form plasmin. Plasmin is important in fibrinoly- 
sis and extracellular matrix (ECM) degradation. El- 
evated levels of plasma PAL1 inactivate the plas- 
minogen activators, which leads to decreased genera- 
tion of plasmin and inhibition of fibrinolysis. It has 
been shown that the hypercoagulable state induced by 
high plasma PAL 1 has been associated with throm- 
botic complications such as deep venous thrombosis ~ 
and myocardial infarction.2 A second function ofplas- 
min important in this work involves activation of pro- 
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teolytic enzymes in the ECM of the arterial wall and 
direct degradation of many components within the 
ECM? Recently published work has identified plas- 
min as the 80 kDa protease that is elevated in abdomi- 
nal aortic aneurysms, suggesting that plasmin- 
induced ECM degradation may be a cause of aneu- 
rysm formation. 4 
The levels of PAl- 1 present in the arterial wall are 
of interest because of its effect on plasmin formation. 
Existing evidence suggests that an excess of PM-I  
decreases active tEA and uPA levels, which leads to 
decreased plasmin formation. This decrease may alter 
tissue remodeling and lead to accumulation ofECM. 
In vitro, a tissue culture model has shown that increas- 
ing the level of PAI-I by stimulating fibrosarcoma 
cells with transforming growth factor-]] inhibits ECM 
degradation. Antibodies to PAI-1 negate this re- 
sponse. 5 PAl- 1 is synthesized by many cells, including 
endothelial cells, vascular smooth muscle cells 
(SMCs), and macrophages. 6 In tissue culture, many 
different cytoldnes elevate PAl- 1 levels in endothelial 
cells r and vascular SMCs. 8 These cytokines also are 
present in atherosclerotic lesions 9and thus may alter 
PAl- 1 synthesis n vivo. 
Many cell types in tissue culture secrete PAl-l, 
which then is bound to the ECM, 1° where vitronectin 
stabilizes it in an active form. n The possible involve- 
ment of PAl-1 in arteriosclerosis has been proposed 
by Sawa et al. ~2 They fed rabbits a high-cholesterol 
diet and observed an increase in plasma PAI-1 and 
ECM-associated vitronectin. These elevations led 
them to speculate that hypercholesterolemia, by in- 
ducing these changes, may potentiate ECM accumu- 
lation and thereby accelerate arteriosclerosis. 
PAl- 1 indirect immunohistochemistry on normal 
arteries has localized it to the intima, media, and vasa 
vasorum of the adventitia. In arteries with arterio- 
sclerosis, PAI-1 also had been detected surrounding 
the lesion, in foam cells, and adjacent to the internal 
elastic lamina in the ECM. 6 In-situ hybridization i  
normal and diseased arteries has been performed by 
two groups. 6,13 Schneiderman et al. ~3 showed intimal 
endothelial cell production of PAl-1 mRNA in nor- 
mal specimens. Atherosclerotic sections were positive 
in the intima and the adventitial vasa vasorum endo- 
thelial cells, within inflammatory cell infiltrates, and 
in cells along the base and sides of the plaque. Lupu 
et al. 6 reported similar findings, except hey also 
identified scattered areas of PAI-1 mRNA in the 
media associated with vascular SMCs of normal ar- 
teries. 
Schneiderman et al. ~3 also demonstrated aneleva- 
tion of PAI-1 mRNA in occlusive and aneurysmal 
aorta when compared with histologically normal 
arteries. They found no differences between the 
aneurysmal nd occlusive specimens, uggesting that 
the elevation of PAI-1 mRNA was associated with 
arteriosclerosis. Although PAI-1 mRNA levels have 
been reported in arteriosclerosis, data on PAI-1 
protein levels are not available in the literature. If 
PAI-1 contributes to arteriosclerosis, then diseased 
vessels hould have elevated levels of this protein. To 
investigate this possibility, we used tissue cxplant 
supernatants, protein extracts, and Northern analysis 
to evaluate normal and atherosclerotic aorta for PAI-1 
levels. In-situ hybridization was used to localize the 
source of PAI- 1 transcripts. 
METHODS 
The following studies were performed with the 
approval of the Institutional Review Board of North- 
western University, and all patients gave informed 
consent. Infrarenal atherosclerotic aortas (aneurys- 
mal and occlusive) were obtained at the time of bypass 
grafting. Normal thoracic and abdominal aortas used 
in the study were procured from organ donors 
through the Regional Organ Bank of Illinois. 
Tissue explant supernatants. In the operating 
room, specimens were placed on ice in holding media 
(Dulbecco's modified Eagle's medium, Ham's F-12, 
16% fetal bovine serum, penicillin/streptomycin, a d 
amphotcricin [5) and processed within 1 to 2 hours. 
Using sterile technique, the tissue was washed with 
phosphate-buffered saline solution (PBS) to remove 
residual thrombus, minced into l× l -mm squares, 
weighed, and placed into 4 ml Roswell Park Memorial 
Institute (RPMI) media with penicillin/streptomycin 
per gram of tissue. The specimens were incubated at 
37 ° C with 5% CO 2 for 48 hours. The supernatant was 
removed, centrifuged, ivided, and stored at -80 ° C. 
Time-course xperiments were performed by minc- 
ing each specimen and evenly dividing the tissue from 
a single patient into six separate tissue-culture flasks. 
The supernatants were collected at 0, 4, 8, 24, 48, and 
72 hours. Protein and RNA synthesis were inhibited 
respectively by cycloheximide (25 btg/ml) and acti- 
nomycin D (5 btg/ml). The inhibitors were dissolved 
in alcohol, added to the RPMI media t time zero, and 
were in contact with the tissue for 72 hours. Control 
flasks contained tissue from the same patient placed in 
the RPMI media-alcohol mixture without he respec- 
tive inhibitors. 
Protein extracts. Tissue from the operating room 
was immediately placed in liquid nitrogen and stored 
at -80 ° C until use. Protein extracts were obtained 
by a previously described method. 14 Briefly, 1 ml 
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Camiolo buffer was added to 100 mg of tissue that 
had been rinsed in PBS and minced. The specimens 
were homogenized for 1 minute at 4 ° C with a 
Polytron homogenizer (Brinkmann I dustries; West- 
bury, N.Y.). The homogenate was centrifuged at 
3000g for 15 minutes at 4 ° C. The supernatant was 
divided and stored at -80 ° C. 
Quantitation of PAI-1. Total PM-1 antigen was 
quantitated with TintElize PM-1 (Biopool Inter- 
national; Ventura, Calif.), an enzyme-linked immu- 
nosorbent assay (ELISA) that recognizes all forms of 
PM-1. Manufacturers instructions for nonplasma 
samples were followed, and interassay variability was 
approximately 5%. 
Northern blot analysis. Total RNA was ex- 
tracted from snap-frozen tissue using the method of 
Chomczynsld and Sacchi. s RNA was quantified by 
measuring absorbance at260 nm, and 20 gg of cellu- 
lar RNA was size-fractionated on a 1% formaldehyde 
agarose gel. The samples were electrophoresed with 
ethidium bromide to verify the integrity of the riboso- 
mal RNA. The RNA was transferred toa nylon mem- 
brane and hybridized overnight. A Prime-It II Kit 
(Stratagenc; LaJolla, Calif.) was used with [a2p] 
deoxyadenosine-triphosphate to synthesize radiola- 
beled probes. A 1.1 kb PM-1 probe (bases 7 to 1105) 
was donated by Du Pont Chemical Corporation 
(Wilmington, Del.), and a 1.0 kb glyceraldehyde- 
3-phosphate dehydrogenasc (GAPDH) probe was 
kindly provided by Dr. Kathy Green (Northwestern 
University, Chicago, Ill.). The signal was quantitated 
with a Fuji Bioimager BAS 2000 (Tole/o) and re- 
ported as pulses minus background ivided by the 
area. Tissue culture RNA from microvascular endo- 
thelial cells, kindly provided by Dr. Tom Lawley (Cen- 
ters for Disease Control; Atlanta, Ga.) and Hcp G2 
cells donated by Dr. Mark Johnson (Northwestern 
University, Chicago, Ill.) were used as positive control 
specimens. The 3.2- and 2.3-kb PM-] bands were 
added together and divided by the GAPDH signal to 
normalize for differences inRNA loading. Before the 
second hybridization, the membrane was stripped in 
boiling 0.1x SSC, 0.1% SDS to remove the bound 
probe. 
In-situ hybridization. Tissue was placed in 
Streck Tissue Fixative (Streck Laboratories; Omaha, 
Neb.) and paraffin-embedded. A 720 base-pair frag- 
ment (bases 385 to 1105 )of the PM- 1 probe used for 
Northern hybridization was obtained by restriction 
digests with Pst I and Sac I. The 720 base-pair PM-1 
fragment was subcloned into PGEM-3Z (Promega; 
Madison, Wis.). Sense and antisense [asS] uracil- 
triphosphate-labeled riboprobes were synthesized 
with buffers from Riboprobe Gemini Systems 
(Promega) according to manufacturers instructions 
(antisense, EcoRI, SP6 RNA polymerase; sense, Hind 
III, T7 RNA polymerase). In-situ hybridization was 
performed as described by Wilcox} 6 Briefly, 5-gm 
sections of tissue were deparaffinized in xylenes, 
placed in 50% ethanol, and fixed in paraformaldehyde. 
A limited digestion with proteinase K was used, and 
tissues were hybridized overnight at 55 ° C with sense 
or antiscnse riboprobes. The slides were placed in ri- 
bonuclease A to degrade the unbound riboprobes, 
washed, and dehydrated with ethanol. After drying 
overnight, he slides were dipped in NTB 2 emulsion 
(Eastman Kodak; Rochester, N.Y.) and stored at 4 ° C. 
All tissue sections were hybridized in triplicate and 
developed at different time intervals, typically 2, 4, 
and 8 weeks. The tissue was countcrstained with he- 
matoxylin and eosin and viewed under light micros- 
copy. A positive signal was detected by a clustering of 
black silver grains over a cell, indicating that tile 
NTB2 emulsion had been exposed to radioactivity. 
Statistics. Analysis of variance and Student's ttest 
(unpaired and paired) were performed, with differ- 
ences considered tobe significant at the p < 0.05 level. 
Results are reported as the average value _ SD. 
RESULTS 
Tissue explant supernatants. PAL 1 was assayed 
in 48-hour supernatants of 19 patients (seven aneu- 
rysms, four occlusive aortas, and eight normal aortas). 
The average patient age was 60 + 13 years for donors 
of the diseased aortas (aneurysms, 66 + 10 years; 
occlusive aortas, 50 + 13 years) and 48 + 13 years for 
donors of the normal aortas. Atherosclerotic aortas 
(aneurysmal nd occlusive) had an average of 776 + 
352 ng PAL 1 per ml of supernatant, whereas normal 
aorta averaged 248 + 98 (p < .005, unpaired Student 
t test). Analysis of variance among the three groups 
revealed p < .05 between aneurysms and normal aor- 
tas and between occlusive and normal aortas, but no 
statistically significant difference between aneurysmal 
(823 ± 332) and occlusive (694 ± 423) specimens. 
Time-point experiments were conducted to see 
how PAL 1 changed over time in the supernatant. A 
total of seven specimens (three aneurysms and four 
normal aortas), whose donors had an average age of 
68 _+ 2 for the aneurysmal and 44 - 18 for the normal 
tissue were assayed, revealing that PAId levels did 
increase over time (Fig. 1). In the four normal 
specimens, PAI-I initially increased and then stayed 
relatively constant after 24 hours. In contrast, the 
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Fig. 1. PAI-1 levels in aortic tissue-explant supernatants increased over time. PM-1 levels 
increased over time in all seven samples. PAI-1 levels in the three aneurysmal specimens (circles) 
continued to rise over the entire 72-hour period. In contrast, PM-1 levels in four normal tissue 
samples (squares) rapidly increased until approximately 24hours and then remained relatively 
constant. 
PM-1 levels in the three aneurysmal specimens con- 
tinued to rise over the entire 72-hour period. 
To determine whether the increase over time was 
the result of active synthesis or cell death with release 
of PM-1, cycloheximide or actinomycin D were 
added to the media to inhibit protein or RNA 
synthesis, respectively. All seven specimens (four an- 
eurysms and three normal specimens) revealed a 
decrease in PM- I  in the treated supernatants as 
compared with the controls at 72 hours, with the 
controls having 478 +-202 ng/ml ,  cycloheximide 
with 155 _ 61, and actinomycin D having 153 _+ 50 
(p < 0.005 for both inhibitors compared with the 
control using a paired Student test). Overall, PM-1 
decreased to approximately one third of control 
values for both cyclohcximide and actinomycin D, 
indicating that active synthesis ofPM- 1 had occurred. 
Time-point and inhibitor experiments were not per- 
formed on occlusive samples because of specimen size 
limitations. 
Protein extracts. PM-1 was assayed in 16 speci- 
mens (seven aneurysms, four occlusives, and five 
normal specimens). The average patient age was 
67 _ 8 years for donors in the atherosclerotic group 
(aneurysmal, 69 _ 10; occlusive, 65 _+ 4) and 38 4- 11 
for the donors of normal specimens. The average 
PM-1 per 100 mg of wet tissue weight was 99 4- 58 ng 
for the atherosclerotic group versus 38 _+ 20 ng for the 
normal specimens (p < 0.05, unpaired Student test). 
Analysis of variance between all three groups did not 
reach statistical significance (p = 0.1). The average 
va lues-SD for the three groups were 105-  53, 
87 -+ 73, and 38 +_ 20 for ancurysms, occlusive speci- 
mens, and normal specimens, respectively. Total pro- 
tein was measured with two different assays from 
Biorad (Richmond, Calif.) based on the Bradford and 
Lowry methods. Both assays gave variable results, 
with differences as high as 40% within the same sample 
(data not shown). Dialyzing the extracts before the 
protein assay did not improve the variance; therefore, 
the groups were compared with tissue wet weight as a 
more consistent denominator. 
Nor thern  analysis. Twelve specimens (five aneu- 
rysms, two occlusives, and five normal specimens) 
were analyzed. The average patient age was 62 +_ 12 
for donors in the atherosclcrotic group (aneurysms, 
68 4. 8; occlusions, 48 4. 1) and 43 ___ 7 years for 
donors of the normal specimens. Addition of the 
two PAI-1 mRNA species mad normalizing to the 
GAPDH signal revealed that the PAI-1 mRNA was 
approximately doubled in the atherosclerotic group 
(0.91 +_ 0.49) as compared with control specimens 
(0.44 _+ 0.27). This relationship remained constant 
when the individual PAI-1 bands were compared. 
Results of Student's unpaired t test approached sig- 
nificance (p = 0.08). Statistical analysis was not per- 
formed on the aneurysms versus the occlusive samples 
because of the small number of occlusive samples. The 
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Fig. 2. PAL 1 Northern blot analysis. 3.2- and 2.3-kb species ofPAI-1 mRNA migrate between 
the 28S and 18S ribosomal bands. Notice the decreased signal of GAPDH in diseased aorta, 
indicating uneven loading of RNA (N, normal samples; A, aneurysms; O, occlusive samples; E 
and H are endothelial cell and Hep G2 tissue culture RNA used as positive control samples, 
respectively). 
averages of the two groups were 0.96 + 0.58 and 
0.77 _+ 0.12 for aneurysms and occlusive samples, 
respectively. Fig. 2 shows the PAL1 and GAPDH 
signals. Notice the increased GAPDH signal on the 
normal samples as compared with the diseased vessels, 
which indicates that more RNA was loaded on these 
lanes. Although spectrophotometer r adings were 
used for loading, they are often inaccurate when 
estimating RNA concentrations. 
In-situ hybridization. Twelve specimens (six 
aneurysms, two occlusive samples, and four normal 
samples) underwent in-situ hybridization with anti- 
sense riboprobes to localize PAL1 mRNA and with 
sense riboprobes as a negative control (Fig. 3). PAI-1 
mRNA was strongly positive in endothelial cells of the 
lumen and the vasa vasorum. Scattered vascular SMCs 
and a few cells that had a shape consistent with 
macrophages were also positive. The large inflamma- 
tory infiltrates common in aneurysmal nd occlusive 
aorta were generally negative for PAL 1 mRNA except 
where they were adjacent to vasa vasorum with 
positive endothelial cells. 
DISCUSSION 
Elevated levels of plasma PAI-1 have been associ- 
ated with many conditions that have thrombotic 
complications, and its role in the inhibition of fibrin- 
olysis is well documented. 17 Recently, a proposed 
second function suggests that elevations of PAL 1 in 
the arterial wall may accelerate arteriosclerosis by 
inhibiting breakdown of ECM. Schnciderman etal.~3 
demonstrated a twofold to threefold elevation of 
PAI-1 mRNA in athcrosclerotic aortas when com- 
pared with histologically normal arteries. They found 
no differences between patients with aneurysmal nd 
occlusive disease, suggesting that PAI-1 mRNA el- 
evations were associated with arteriosclerosis. Our 
RNA data confirms this observation. We detected a
twofold increase in athcrosderotic PAL1 mRNA 
when compared with levels in normal aorta. 
Immunohistochemistry andelectron microscopic 
observations have revealed the presence ofintracellu- 
lar PAI-1 in endothelial and vascular SMCs. PAI-1 is 
also found in the ECM where it colocalizes with 
vitronectin. 6 Ours is the first report that quantitates 
PAI-1 protein in normal and atherosclerotic vessels. 
Using two different methods, we demonstrated el- 
evations of PAI-1 protein in atherosclerotic aorta. 
The technique of tissue explant supernatants was 
selected as a dynamic assay and showed that PAI- 1 was 
actively being synthesized, even under serum-free 
conditions. Supernatant time-course experiments re- 
vealed that PAL1 levels increased over time in both 
diseased and normal aortic tissue. Inhibition of pro- 
tein or RNA synthesis by the addition of cyclohexi- 
mide or actinomycin D decreased PAL1 to one third 
of control evels. This finding is of interest because it
suggests that the majority ofPAI- 1 in the supernatant 
is the resttlt of active synthesis and not release caused 
by cell death. The second method, that of protein 
JOURNAL OF VASCULAR SURGERY 
Volume 23, Number 5 Shireman et al. 815 
Fig. 3. PM-1 in-situ hybridization. A, In this aortic arteriole, PM-1 mRNA localizes to 
endothelial cells ofvasa vasorum (arrow). Original magnification, 40x. B, Sense PM-1 probes, 
used as negative control sample, revealed no binding to endothelial cell vasa vasorum. Original 
magnification, 40x. C, Vascular SMC positive for PM-1 mRNA. Original magnification, 100x. 
D, Section of aneurysm shows positive lumenal endothelial ceils (solid arrow) and scattered 
positive intimal cells (open arrow). Original magnification, 40x. 
extracts, is a static assay and reflects the amount of 
PM- 1 that is present in the arterial wall at the time of 
specimen harvest. Our data show elevations of PAl-1 
in atherosclerotic ascompared with normal aorta in 
both assays. 
Endothelial cells are thought o be a significant 
producer of PAI-1 in vivo. Is Our current findings, 
using in-situ hybridization, localized PAl- 1 mRNA to 
both the lumenal and vasa vasorum endothelial cells in 
normal and diseased aorta. In addition, scattered vas- 
cular SMCs and inflammatory ceils were also positive. 
The inflammatory infiltrate, commonly seen in aneu- 
rysmal and occlusive aorta, was generally negative. 
Instead, scattered ceils with a shape consistent with 
macrophages were positive. These findings are consis- 
tent with the results of previous investigators. 6'13 
A trend toward higher PM-1 levels in ancurysms 
than occlusive samples was observed in both the tissue 
explant supernatants and protein extracts, although 
the differences were not statistically significant. This 
finding can be explained speculatively b  two different 
mechanisms. PM-1 is tightly bound to the ECM. 
Aneurysms are heterogeneous, consisting of areas of 
ECM accumulation and attenuated areas with ECM 
degradation. Perhaps the PM-1 in the degraded areas 
is not as tightly adherent to he ECM and is therefore 
more easily extracted. In addition, the occlusive 
specimens were taken from the proximal aortic suture 
line, not from the area with the greatest stenosis. 
Mthough these specimens contained atherosclerotic 
lesions, they did not include the most severely dis- 
eased areas. In contrast, the specimens with aneu- 
rysms were taken from the anterior middle-portion of
the aneurysm wall, which is consistently atheroscle- 
rotic. 
Patient age is another factor that is difficult to 
exclude as a cause for the observed increase in PAI-1 
levels in atherosclerotic versus normal aorta. We are 
not aware of any published studies that show an 
association between increased age and PAI- 1 levels. In 
the tissue-explant supernatants, the patients with 
aneurysms were older than donors of the normal 
specimens, with average ages of 66 and 48 years, 
respectively. The patients with occlusive disease, how- 
ever, had an average age of 50 years, which was very 
similar to the normal group. There was a statistically 
significant difference in the levels of PAI-1 in normal 
versus occlusive aorta. Furthermore, there was no 
significant difference between the PAl-1 levels in the 
aneurysmal and occlusive groups despite the in- 
creased age of the aneurysm patients as compared 
with the occlusives. In addition, the patients in the 
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normal  group were all 44 years o f  age or older, except 
for one patient who was 18 years old. The 18-year-old 
had the second-highest level of  PAI-1 in the normal  
group. These observations suggest hat the elevated 
PAI- 1 levels are not  associated with increasing age but  
rather the arteriosclerosis present in the diseased 
specimens. 
Because PAI-1 inhibits the plasminogen activa- 
tors, levels o f tPA  and uPA in aortic tissues are o f  great 
interest. Two different studies that examined plas- 
minogen activator levels in normal,  aneurysmal, and 
occlusive aorta have been reported,  with confl icting 
results. Us ing protein extracts, Reilly et al. 14 demon-  
strated a significant difference in tPA levels between 
all three aortic groups, with aneurysms exhibit ing the 
highest level, fol lowed by normal  aortas and then 
occlusive aortas. They were unable to quantitate uPA 
levels in the specimens, a l though they did demon-  
strate the presence o f  uPA by fibrin autography. In 
contrast, Shireman et al., 19 by using tissue explant 
supernatants, demonstrated similar levels o f  tPA in 
aneurysmal nd occlusive aorta, which were threefold 
higher than the tPA levels found in normal  specimens. 
Significant differences in the levels o f  uPA were 
demonstrated between all three groups, with aneu- 
rysms exhibit ing the highest levels, fol lowed by oc- 
clusive specimens and then normal  specimens. Fur- 
ther research is needed to clarify the role o f  the 
plasminogen system in these disease processes. 
CONCLUSION 
We have demonstrated elevated levels o f  PAI-1 
protein in atherosclerotic aorta using tissue explant 
supernatants and protein extracts. In addit ion, this 
elevation was also observed in the mRNA,  which 
suggests that the increase in PAI-1 is control led at the 
level o f  transcription. PAI- 1 mRNA was localized to 
endothel ial  cells and to scattered vascular SMCs and 
inf lammatory cells. We were unable to determine 
whether  increased PAI-1 results in arteriosclerosis or
whether  it is caused by arteriosclerosis. Elevated levels 
ofPAI -  1 in the plasma, by inhibit ing the plasminogen 
activators that convert p lasminogen into its active 
form, have been shown to inhibit  fibrinolysis. This 
same inhibit ion o f  the plasminogen activators could 
occur in the arterial wall, leading to decreased ECM 
degradation,  which may cause arteriosclerosis. We 
conclude that elevated levels ofPAI -  1 exist in diseased 
aorta and may lead to altered tissue remodel ing,  
thereby contr ibut ing to the arteriosclerosis found in 
aneurysmal and occlusive aorta. 
We thank Dr. David Loskutoffand Mrs. Terri Thinnes 
of the Scripps Research Institute for their valuable assistance 
with in-situ hybridization, and Dr. Joseph Feinglass and Dr. 
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DISCUSSION 
Dr. Howard P. Greisler (Maywood, Ill.). I would like 
to congratulate Dr. Shireman not only for her excellent 
presentation but also for the thoroughness of her experi- 
mental design and her data interpretation. A growing body 
of evidence suggests that an early up-regulation of plas- 
minogen activator expression by SMCs after balloon de- 
endothelialization injury is required for ECM degradation, 
permitting SMC migration leading to intimal hyperplasia. 
However, the role of proteolytic enzymes in general and 
plasminogen activators and plasminogen activator inhibi- 
tors in atherosclerosis remains more enigmatic. This article 
confirms previous reports of an increase in PAI-1 mRNA in 
diseased versus normal human aortas and extends this to 
also show a correlating difference in PAI-1 protein expres- 
sions. The authors uggest that an increased PAI-1 expres- 
sion may lead to wall-thickening by inhibiting ECM deg- 
radation. 
Proteolytic activity, however, depends on the balance of 
activity between the plasminogen activators tPA and uPA 
and their inhibitors, predominantly PAI-1. Do the authors 
have data on PA expression in these tissues so that 
PA/PAI-1 ratios can be compared and then perhaps also 
correlated with the concentration of structural proteins? 
In an article in the current issue of Arteriosclerosis, 
Thrombosis and Vascular Biology, Elliott Barnathan at Penn 
found no differences inPAI-1 between diseased and normal 
human coronary arteries, but did find that diseased arteries 
expressed more tPA and more uPA receptor (uPAR) in the 
intimas compared with normal coronary arteries. Sobel also 
showed increased uPAR at the base of diet-induced early 
lesions in rabbits, and Luper showed an increase in uPA 
dependent lyric activity in diseased arteries using zymogra- 
phy. These studies together suggest hat even if PAI-1 is 
increased, both PA and, more importantly, PA activity may 
be even more increased. Although the author's uggestion 
that an increase in antiproteolytic activity may result in 
wall-thickening is certainly valid, one may also speculate 
that the opposite is true, that is, an increase in proteolytic 
activity may stimulate atherosclerosis either by promoting 
cell migration or by destabilizing plaque or wall thrombus. 
My questions for the authors are as follows. First, do we 
have data as to the expression of tPA and uPA in diseased 
versus normal tissues? Second, the data on diseased tissues 
necessarily represents late lesions. The control group used 
tissues from patients who were an average of 15 years 
younger. I f  these patients were to develop atherosclerosis, 
clearly an assumption, might this not suggest han an 
increase in PAl-1 expression does not occur early in lesion 
formation? Related to that question, both normal thoracic 
aorta and abdominal orta was collected from some donors. 
Because these sites have a different likelihood of developing 
disease, did the authors compare PAI-1 expression between 
thoracic and abdominal aorta? Last, even if PAI-1 expres- 
sion is increased inearly lesions, can the authors peculate on 
a model in which to test the pathophysiologic role of that 
increased expression i  lesion development? 
Finally, I would like to point out the elegance that the 
authors used in carrying out studies by which protein 
concentration in snap-frozen tissue validated that the results 
derived from ex-vivo tissue culture experiments were not 
likely to be culture artifacts, and the use of Northern analysis 
standardizing results to GAPDH controls and the use of 
transcription and translation i hibition suggests that these 
protein results were a function of cellular protein rather than 
simply ECM-associated stored pools. Attention to these 
details greatly strengthen the importance of the data. 
Dr. Paula Shireman. To address the first question on 
plasminogen activator levels, we measured the levels of 
plasminogen activators in these series of experiments, tPA 
and uPA are the two main activators. The tPA is higher in 
atherosclerotic aorta as compared with control aortas, and 
aneurysmal and occlusive aorta do not differ. The uPA, 
however, is differentially expressed, with the highest level 
demonstrated in aneurysms, intermediate l vels shown in 
occlusive aortas, and almost undetectable vels in the 
normal aortas. I think you are right. These experiments u ed 
whole pieces of tissue in an attempt to find a total evel of the 
plasminogen activators. It is really going to be more 
important to see where the uPA, tPA, and PAI-1 localizes 
within the aortic wall. All the PAI- 1 in the world is not going 
to inhibit the plasminogen activators if they are not in the 
same location. 
As for your second question, regarding the differences 
in ages between the diseased and normal aortas, obtaining 
control aorta is always difficult, and as these experiments 
show, we need fresh tissue or the RNA is degraded. Also, as 
demonstrated in the tissue-explant supernatant experiment, 
PAI-1 is actively synthesized. We did have the fortunate 
circumstances of having a donor population that was 
relatively age-matched to the donors of the occlusive aortas. 
The age range in the donors of normal aortas of 18 to 59 
years is a little misleading, as we had one 18-year-old. 
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Otherwise the age range was 49 to 59 years, which is very 
comparable with the occlusive population. A statistically 
significant difference was found between PAL1 levels in 
these two age-matched groups. No statistically significant 
difference was found between the occlusive and aneurysmal 
groups, even though the patients with aneurysms tended to 
be about 15 to 20 years older than patients in the occlusive 
group. It is also of interest to note that the 18-year-old had 
the second-highest level of PAI-1 in the normal category. 
We think that he difference in PAL 1 levels is probably more 
reflective of the disease state rather than a function of age. A 
paper by Loskutoff and Schneiderman demonstrated that 
elevations of PAI-1 mRNA correlated with the histologic 
severity of the atherosclerotic lesion. 
As for the third question, that is probably aNobel Prize 
winner. I think it is vcry difficult o predict future therapeu- 
tic strategies in arteriosclerosis because there are really no 
good animal models to study, and it is a disease that starts 
when a person is a couple of days old and then finally causes 
symptoms mostly after the age of 50 years. People have been 
worldng with the antisense nucleotides with either DNA or 
RNA in an attempt to try to block the mRNA of the PAId 
so that it is not expressed. I think that eventually we need to 
have a much greater understanding of what actually turns on 
the genes in arteriosclerosis. Prevention of atherosclerotic 
disease would be the best therapeutic option rather than 
treatment ofthe symptoms it causes. To do that, we would 
need a lot more insight into the genes that are abnormally 
expressed in arteriosclerosis. 
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